Skip to content

Comparative study of effectiveness of intravenous high dose of vitamin C and vitamin B1 in patients with severe infection.

To compare efficacy of high dose Vitamin C infusion and Thiamine (vitamin B1) infusion in patients of sepsis. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063852
Enrollment
75
Registered
2024-03-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B978- Other viral agents as the cause ofdiseases classified elsewhere Health Condition 2: B348- Other viral infections of unspecified site Health Condition 3: O85- Puerperal sepsis Health Condition 4: A419- Sepsis, unspecified organism Health Condition 5: B999- Unspecified infectious disease

Interventions

Intervention1: High dose vitamin C infusion in patients of sepsis: The patient of this group will receive 2.5 gram vitamin C, 8 hourly( total dose 7.5 gram/day) for 5 days as an intavenous infusion mi

Sponsors

Uttar Pradesh University of medical sciences saifai etawah
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with body mass index between 18 to 30 2.Patient who will not be on mechanical ventilator but fulfilling the criteria of sepsis at the time of inclusion for study 3.Patient who will be on standard treatment with similar antibiotics 4.Patient with SOFA score more than 2 but less than 8 will be included in the study.

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding females 2.Moribund and not expected to survive 96 hours 3.Cancer as the cause of sepsis 4.Patients with chronic kidney disease, chronic alcoholics and immuno-compromised patients.

Design outcomes

Primary

MeasureTime frame
To compare the SOFA (Sequential Organ Failure Assessment) score.Timepoint: 6 days

Secondary

MeasureTime frame
1. Incidence of ventilator associated pneumonia (VAP) if patient requires mechanical ventilation after inclusion in study. 2. Duration of vasopressor therapy 3. CRP levels 4. Length of hospital stay 5. Mortality 6. Serious adverse events like ARDS, pulmonary embolism.Timepoint: 6 days

Countries

India

Contacts

Public ContactDr Sonali Agrawal

Uttar Pradesh University of medical sciences Saifai Etawah

drprashant.mishra@yahoo.com9455677608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026